PT  - JOURNAL ARTICLE
AU  - Alshahrani, Ali A.
AU  - Qahtani, Saad S. Al
AU  - Qahtani, Abrar S. Al
AU  - Mashhour, Saeed M.
AU  - Alkhtani, Zayed S.
AU  - Alragea, Yahya M.
TI  - Metabolic and renal outcomes of empagliflozin in patients with type 2 diabetes mellitus attending Armed Forces Hospital in Saudi Arabia
AID  - 10.15537/smj.2023.44.7.20230094
DP  - 2023 Jul 01
TA  - Saudi Medical Journal
PG  - 674--678
VI  - 44
IP  - 7
4099  - http://smj.org.sa/content/44/7/674.short
4100  - http://smj.org.sa/content/44/7/674.full
SO  - Saudi Med J2023 Jul 01; 44
AB  - Objectives: To explore the effects of empagliflozin (25 mg) on metabolic and renal parameters in patients with type 2 diabetes mellitus (T2DM).Methods: This retrospective observational comparative study was conducted at a military hospital in southern Saudi Arabia. All adults (aged >18 years) with T2DM who attended diabetic clinics between October 2021 to March 2022 (6 months), with or without insulin treatment, were eligible for inclusion in the study.Results: Following the initiation of empagliflozin treatment, statistically significant reductions in patient weight (kg) were observed at 1, 3-5, and 6 months. In addition, low-density lipoprotein levels significantly decreased 3-5 months post-treatment initiation (p=0.011). However, serum creatinine level decreased gradually with time during the treatment with empagliflozin, from 87.45±31.78 (0.105) to 78.39±27.43 (0.033). Furthermore, after empagliflozin treatment, the urinary albumin-to-creatinine ratio significantly decreased at 3-5 and 6 months. Moreover, HbA1c levels exhibited statistically significant decreases at 3-5 months (p<0.001) and at 6 months (p<0.001) following the initiation of empagliflozin treatment. Notably, systolic and diastolic blood pressure significantly reduced 6 months after empagliflozin treatment.Conclusion: In the current study, empagliflozin has demonstrated efficacy in controlling blood pressure and body weight, and improving renal function, short-term dyslipidemia, and glycemic control in patients with T2DM.